A5024360451- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Head and Neck Surgical Oncology
- Advanced Radiotherapy Techniques
- Acute Kidney Injury Research
- Chemotherapy-induced organ toxicity mitigation
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Cutaneous Melanoma Detection and Management
- Chronic Kidney Disease and Diabetes
- Digital Mental Health Interventions
- Childhood Cancer Survivors' Quality of Life
- Melanoma and MAPK Pathways
- Lymphoma Diagnosis and Treatment
- Family Support in Illness
- Cancer survivorship and care
- Nonmelanoma Skin Cancer Studies
- Ear and Head Tumors
- Palliative Care and End-of-Life Issues
Rush University
2024-2025
Rush University Medical Center
2019-2024
Memorial Sloan Kettering Cancer Center
2022
University of Chicago
2015-2021
Australian Catholic University
2014
The University of Melbourne
2014
St Vincent's Hospital
2014
Neoadjuvant immunotherapy in human papillomavirus (HPV)-negative locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) appears promising, yet its role nonsurgical treatment for cancer remains undefined. nivolumab plus chemotherapy followed by response-stratified de-escalated chemoradiation therapy (CRT) HPV-negative LA stage IVa/b HNSCC may improve efficacy while reducing treatment-related toxic effects. To determine the deep response rate tolerability of neoadjuvant CRT...
Head and neck squamous cell carcinoma (HNSCC) frequently affects elderly patients. Given the frailty comorbid conditions of this population as well potential toxicities associated with treatment, there is a risk undertreatment in older However, growing evidence that benefit standard treatment similar younger Few prospective trials specifically target elderly, which forces clinicians to rely on subgroup analyses retrospective data. Therefore, adequate pretreatment assessments are vital...
6007 Background: The role of neoadjuvant immunotherapy in curative-intent head and neck squamous cell carcinoma (HNSCC) remains poorly defined. Survival for locoregionally advanced (LA) HPV negative (-) HNSCC poor with two-year survival ~50%, substantial treatment-related toxicity standard chemoradiation (CRT). Given the activity anti-PD1 recurrent/metastatic HNSCC, we studied nivolumab chemotherapy feasibility subsequent response-stratified CRT HPV(-) LA HNSCC. Methods: DEPEND trial...
9616 Background: Stereotactic body radiotherapy (SBRT) provides high rates of treated metastasis control, stimulates innate and adaptive immune pathways, is safe in patients with anti-PD1 monotherapy following SBRT. We hypothesize that SBRT may improve outcomes for receiving immunotherapy through both direct cytoreduction increased immunogenicity. Within this context, we conducted a phase 1 trial designed to evaluate the safety combination checkpoint blockade nivolumab ipilimumab(N/Ip) plus...
Abstract Acute kidney injury (AKI) limits cisplatin use. We tested whether urine cystatin C (uCyC) and neutrophil gelatinase‐associated lipocalin (uNGAL) can preidentify patients at risk for AKI. Patients initiating cisplatin‐based chemotherapy were prospectively enrolled. uNGAL/uCyC measured pre/post‐cisplatin administration compared with serum creatinine (sCr). AKI was defined as sCr increase ≥50% or ≥0.3 mg/dL above baseline. In all, 102 enrolled; 95 provided evaluable data. Twenty‐five...
Stereotactic body radiotherapy (SBRT) provides high rates of treated metastasis control, stimulates innate and adaptive immune pathways, is safe in patients with anti-PD1 monotherapy. We hypothesized that SBRT may improve outcomes for receiving immunotherapy through direct cytoreduction increased immunogenicity. designed a phase 1 trial to evaluate the safety combination checkpoint blockade nivolumab ipilimumab (N/Ip) plus sequential (Seq) or concurrent (Con) multisite as first-line therapy...
6031 Background: This phase I/II study evaluates safety and efficacy of veliparib, a PARP inhibitor, with induction carbo-tax in patients (pts) locoregionally advanced HNSCC. Since is involved DNA repair, inhibition may augment damaging effects chemotherapy on tumor DNA. We report the completed I portion trial. Methods: Eligible pts had newly diagnosed stage IVa-b non-oropharyngeal cancer (OPC) or IVa-b, human papillomavirus-negative OPC. The primary endpoint maximum tolerated dose (MTD)...
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is the new first line standard of care in metastatic non-small cell lung cancer (NSCLC) based on improvements overall survival (OS), control central nervous system (CNS) disease, and superior toxicity profile. This commentary highlights interim results from ADAURA trial, continuing effort to establish role for TKIs adjuvant setting.
e18009 Background: Cancer vaccines may expand intratumoral CD8+ T cells, potentially increasing response rates to PD-1 blockade. SNS-301 is a bacteriophage-based cancer vaccine against aspartate β- hydroxylase (ASPH), prevalent tumor-associated antigen. The objectives of this Phase 1/2 study were evaluate the safety, immunogenicity and preliminary efficacy plus pembrolizumab in patients (pts) not achieving tumor reductions on blockade alone (Cohort A) or naïve B). Methods: This trial...
We aim to describe outcomes of elderly patients undergoing salvage surgery for laryngeal cancer and characterize the interplay age with various other factors in this growing population.Using National Cancer Database, we identified cases laryngectomy who failed chemoradiation. An cutoff 70 years was used separate subjects into two groups. Various were compared.Of 825 included, 166 (20.1%) elderly. Elderly had worse overall survival (p = 0.001), higher 30-day 90-day mortality 0.006, p < a...
Abstract Recently, we described a phenomenon whereby apoptotic cells generate and release CrkI-containing microvesicles, which stimulate proliferation in surrounding upon contact to compensate for their own demise. We termed these microvesicles “ACPSVs” Apoptotic Compensatory Proliferation Signaling microvesicles. As immune majority of current cancer therapeutics destroy tumor primarily by apoptosis, conducted small pilot study assess the possibility that ACPSVs may also be generated...
Introduction With the incorporation of modernized radiotherapy, chemotherapy, and immunotherapy, treatment outcomes have improved for patients with locally advanced, unresectable diseases. Elderly or poor performance status comprise more than half non-small cell lung cancer (NSCLC) patients, but they are often underrepresented excluded in clinical trials. Split-course concurrent chemoradiotherapy can be an effective treatment, showing good adherence a favorable toxicity profile unresectable,...
317 Background: CDDP-based treatment is limited by AKI. We aimed to test whether a novel AKI biomarker, uCyC, measured before and immediately after CDDP administration could permit earlier identification of UC pts at risk for Methods: In nested case-control study, treated with were prospectively enrolled. uCyC was 2 hours pre- 3 post-CDDP doses, values normalized urine creatinine. defined as an increase in serum creatinine (sCr) ≥50% (severe cases) or ≥0.3 mg/dL above pre-CDDP baseline....
There is significant variation in post-treatment surveillance imaging for sinonasal malignancies. This study examined the utility of detecting recurrence patients treated malignancies.We performed a retrospective review on an IRB-approved dataset with malignancies at single institution between 2005 to 2021. Patients were categorized into groups based frequency annual and total number studies. We compared time-to-recurrence using log-rank test. A two-sided p-value <0.05 was considered as...